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Regulation of B Cell Linker Protein Transcription by PU.1
and Spi-B in Murine B Cell Acute Lymphoblastic Leukemia
Li S. Xu,*,† Kristen M. Sokalski,*,† Kathryn Hotke,*,† Darah A. Christie,*,† Oren Zarnett,*,†
Jan Piskorz,*,† Gobi Thillainadesan,‡,x Joseph Torchia,‡,x and Rodney P. DeKoter*,†,{

A

cute lymphoblastic leukemia (ALL) is the most common
form of cancer in young children (1). Despite a better
than 80% cure rate, ALL represents a leading cause of
leukemia-related deaths in children and upon relapse in adults (1).
The majority of human ALLs are cancers of the B lymphocyte
lineage (B cell ALL [B-ALL]) and are frequently associated with
mutations or chromosomal translocations targeting genes encoding transcription factors (2). For example, 25% of cases of pre-B
ALL have the t(12;21) chromosomal translocation, resulting in
a fusion between the ETV6 and RUNX1 genes encoding the
transcription factors TEL and AML1, respectively (1). The E26transformation–specific transcription factor PU.1, encoded by the
gene Sfpi1 in mice and SPI1 in humans, is required for generating
lymphoid progenitor cells and is a key regulator of B cell fate
specification (3, 4). SPI1 mutations are associated with human
AML (5, 6) and B-ALL (7). Reduced PU.1 expression is sufficient
to induce AML in mice (8, 9). Reduced PU.1 levels are also associated with human lymphoid leukemia and lymphoma (10, 11).
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Spi-B (encoded by Spib) is expressed in developing B cells (12),
and it interacts with DNA binding sites thought to be identical to
those recognized by PU.1 (13). Reduced Spi-B expression was
recently associated with human B-ALL (14). Our laboratory
previously showed that mice that lack both PU.1 and Spi-B in
the B cell lineage (CD19+/CreSfpi1lox/loxSpib2/2 mice, henceforth
known as DPB mice) have impaired B cell development and develop B-ALL with 100% incidence rate by 21 wk of age (15).
These results demonstrate that PU.1 and Spi-B have tumorsuppressor function in the B cell lineage and suggest that mutation of the SPI1 and SPIB genes, or upstream activators of these
genes, could be oncogenic drivers in leukemia-initiating cells.
Because these proteins are transcription factors, it is important to
identify target genes that could explain the role of PU.1 and Spi-B
in lymphoid leukemogenesis.
B cell linker protein (BLNK, also known as SLP65 or BASH) is
an adaptor protein that is required for B cell development as
a consequence of its important role in BCR signaling (16–18).
BLNK links BCR signaling with enforcement of B cell differentiation by mediating interactions between Syk, Vav, PLCg2, Grb2,
and Bruton’s tyrosine kinase (Btk) upon phosphorylation by Syk
(19, 20). Inactivating mutations of BLNK are associated with BALL in human patients (21, 22), and reduced expression of BLNK
has also been associated with B-ALL (23). In mice, mutation of
Blnk is sufficient to induce B-ALL with a 10% incidence rate (23,
24). Therefore, BLNK has important roles in enforcing B cell
differentiation and functions as a tumor-suppressor gene.
We previously noted that levels of Blnk mRNA transcripts were
reduced in sorted splenic DPB B-ALL cells compared with control
B cells (15). Therefore, we hypothesized that Blnk is a target of
transcriptional activation by PU.1 and/or Spi-B. To test this hypothesis, we performed a detailed characterization of B-ALL cells
from DPB mice. DPB B-ALL cells expressed high levels of IL7Ra and grew in culture in response to IL-7. Cultured DPB BALL cells expressed reduced levels of BLNK mRNA transcripts
and protein compared with control cells. The Blnk promoter was
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B cell acute lymphoblastic leukemia (B-ALL) is frequently associated with mutations or chromosomal translocations of genes
encoding transcription factors. Conditional deletion of genes encoding the E26-transformation–specific transcription factors, PU.1
and Spi-B, in B cells (DPB mice) leads to B-ALL in mice at 100% incidence rate and with a median survival of 21 wk. We
hypothesized that PU.1 and Spi-B may redundantly activate transcription of genes encoding tumor suppressors in the B cell
lineage. Characterization of aging DPB mice showed that leukemia cells expressing IL-7R were found in enlarged thymuses. IL7R–expressing B-ALL cells grew in culture in response to IL-7 and could be maintained as cell lines. Cultured DPB cells expressed
reduced levels of B cell linker protein (BLNK), a known tumor suppressor gene, compared with controls. The Blnk promoter
contained a predicted PU.1 and/or Spi-B binding site that was required for promoter activity and occupied by PU.1 and/or Spi-B
as determined by chromatin immunoprecipitation. Restoration of BLNK expression in cultured DPB cells opposed IL-7–dependent proliferation and induced early apoptosis. We conclude that the tumor suppressor BLNK is a target of transcriptional
activation by PU.1 and Spi-B in the B cell lineage. The Journal of Immunology, 2012, 189: 3347–3354.
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confirmed as a direct target of activation by PU.1 and/or Spi-B
using transient transfection and chromatin immunoprecipitation
(ChIP) analysis. Finally, we showed that forced expression of
BLNK in cultured DPB B-ALL cells opposed proliferation by
inducing early apoptosis. We conclude that the tumor suppressor
BLNK is a target of transcriptional activation by PU.1 and Spi-B
in the B cell lineage.

Materials and Methods
Breeding and care of mice
Mice used in this study were on the C57BL/6 background and were
generated by mating CD19+/CreSfpillox/loxSpib2/2 (DPB) males to CD19+/+
Sfpillox/lox Spib2/2 (DB) females, and genotyped as previously described
(15). Mouse care was monitored under an approved animal use protocol in
accord with the University of Western Ontario Council on Animal Care.

Cell culture

Colony-forming assays
DPB cells or retrovirally infected DPB cells were plated in methylcellulose
media containing recombinant murine IL-7 (MethoCult 03630; Stem Cell
Technologies, Vancouver, BC, Canada) and incubated for 7 d at 37˚C and
an atmosphere of 5% CO2. Colonies were scored and visualized using
a Zeiss A-plan 53/0.12 Pho 441021-9910 objective lens on an Axio Observer A1 microscope (Carl Zeiss MicroImaging, Thornwood, NY).

Flow cytometric analysis and immunoblotting
Abs used in this study were purchased from eBioscience (San Diego, CA)
and included biotin anti–pre-BCR (clone SL156), biotin anti-IgM (II/41),
PE anti–c-Kit/CD117 (2B8), biotin anti-CD45R/B220 (2A3-6B2), biotin
anti–IL-7Ra/CD127 (B12-1), PE-conjugated anti-CD93 (AA4.1), FITCconjugated anti–BP-1 (6C3), and PE-, allophycocyanin-, or Cy5-conjugated
streptavidin as secondary reagents. Alexa Fluor 647-Annexin V was purchased from BioLegend (San Diego, CA). Flow cytometric analysis was
performed using a BD FACSCalibur system (BD Biosciences, Franklin
Lakes, NJ). Data analysis was performed using FlowJo 9.4.10 Software
(Tree Star, Ashland, OR). All analyses shown are gated on a viable
lymphocyte population based on forward and side scatter values. Immunoblotting was performed using standard methods or as previously published (26). Abs used included rabbit anti-Akt, rabbit anti–phospho-Akt,
rabbit anti-BLNK (Cell Signaling Technology, Beverly, MA), rabbit antiPU.1 (Santa Cruz Biotechnology, Santa Cruz, CA), goat anti–b-actin
peptide Ab (Santa Cruz), HRP-conjugated anti-rabbit or anti-goat secondary Abs (Pierce Biotechnology, Nepean, ON, Canada), and Supersignal
West Pico Chemiluminescent Substrate (Thermo Scientific, Rockford, IL).

Bioinformatics analysis
Phylogenetic comparison of the upstream region of the Blnk gene from
human and mouse was performed using MacVector 11.0 (Accelrys, San
Diego, CA) using sequences obtained from the Ensembl.org database.
Identification of potential E26-transformation–specific binding sites within
the upstream region of the Blnk gene was performed using the application
MATINSPECTOR (Genomatix, Munich, Germany) (27).

Plasmid construction
A 405-bp region upstream of the translation start site in the mouse Blnk
promoter was amplified by PCR using LA-TAQ (TaKaRa; Fisher Scientific, Toronto, ON, Canada), and 59 and 39 HindIII recognition sites were

added to the PCR primers. The PCR fragment was cloned using the
StrataClone PCR Cloning Kit (Agilent Technologies Canada, Mississauga,
ON, Canada). A HindIII fragment containing the Blnk promoter was ligated in forward and reverse orientation into the HindIII site of pGL3basic (Promega, Madison, WI). To obtain pGL3-Blnk-MUT plasmid, we
subjected the pGL3-Blnk-FWD to site-directed mutagenesis using the
QuikChange Lightening Site-Directed Mutagenesis Kit (Agilent). Blnk
cDNA was generated from RNA isolated from spleen of a C57B1/6 mouse
using the RNA-Bee isolation reagent (Tel-Test, Friendswood, TX) and
reverse transcribed using the iScript kit (Bio-Rad Canada, Mississauga,
ON, Canada). The 1501-bp Blnk cDNA was amplified by PCR using LA-TAQ
(TaKaRa) and cloned using the StrataClone PCR Cloning Kit (Agilent). An
EcoR1 fragment containing the Blnk cDNA was ligated into the EcoR1 site
of MIGR1. To generate MIG-3XFLAG-PU.1 and MIG–3XFLAG–Spi-B,
we used PCR to amplify the 3XFLAG coding sequence from the plasmid
vector pBICEP–CMV-2 (Sigma-Aldrich) to introduce a 59 XhoI site and
retain an in-frame NotI site. This DNA fragment was cloned and ligated
into the retroviral vectors MIG-HA-PU.1 and MIG–HA–Spi-B (28) using
XhoI and NotI sites to replace the hemagglutinin epitope tag sequence of
this vector. All constructs were confirmed by DNA sequencing. Oligonucleotide sequences are listed in Supplemental Table I.

Retroviral production and infection
MIGR1, MIG-3XFLAG-PU.1, MIG–3XFLAG–Spi-B, and MIG-BLNK
retroviruses were generated by transient transfection of Plat-E packaging
cells (29) using polyethylenimine transfection at a 3:1 polyethylenimine/
DNA ratio (30). Virus-containing supernatants were collected at 48 h
posttransfection, and viral titers were measured by infection of NIH-3T3
cells. Infections were performed by “spinoculation” with high-titer virus
by centrifugation at 2000 3 g for 3 h at 32˚C in the presence of 8 mg/ml
polybrene. After centrifugation, cells were washed and cultured for 48 h to
promote retroviral integration and gene expression. Infection frequencies
were detected by flow cytometric analysis of GFP.

Transient transfection and ChIP analysis
Transient transfection of WEHI-279 cells was performed using electroporation as previously described (31). MIGR1, MIG-3XFLAG-PU.1, and
MIG–3XFLAG–Spi-B–infected WEHI-279 clonal cell lines were crosslinked with 1% formaldehyde for 10 min at room temperature. ChIP
was performed as previously described (31). Enrichment was measured
using quantitative PCR (qPCR) of DNA immunoprecipitated with antiFLAG magnetic beads (Sigma-Aldrich), using primers indicated in Supplemental Table I. Percentage of input was calculated using the comparative threshold cycle method (32).

Statistical analysis
All data are reported as mean 6 SD of the mean. Statistical significance
was determined using a Student t test unless otherwise indicated. The
p values ,0.05 were considered significant. Statistical analysis was performed using Prism 5.0 (GraphPad Software, La Jolla, CA).

Results
Leukemia cells in the thymus of DPB mice express IL-7Ra
Mice that lack PU.1 and Spi-B in the B cell lineage (DPB mice)
require euthanasia at a median age of 21 wk as a consequence of
lethal B-ALL (15). Leukemia cells infiltrate all lymphoid tissues
in these mice, but the proximal cause of death is dyspnea associated with an enlarged thymus (15). To determine whether thymus enlargement is age dependent, groups of DPB mice were
analyzed at various ages between 6 and 23 wk. Thymuses were
never enlarged in mice aged 6–10 wk (0/8). However, thymuses
were enlarged in 6 of 9 mice aged 11–18 wk and 11 of 12 mice
aged 19–23 wk (Fig. 1A). The weight of enlarged thymuses in 19to 23-wk-old DPB mice was .10-fold greater than that of littermates that lack only Spi-B (DB; Fig. 1B). To confirm the identity
of cells in enlarged thymuses of DPB mice, we performed flow
cytometric analysis. Every enlarged thymus, regardless of age,
contained .90% CD19+ cells, indicating that they were of the
B cell lineage (Fig. 1D). All CD19+ B-ALL cells also expressed
cell-surface IL-7Ra (CD127; Fig. 1C, 1D). The one thymus that
was not enlarged in the 19- to 23-wk age group (Fig. 1A, right
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DPB B-ALL cells were cultured in IMDM (Lonza, Shawinigan, QC,
Canada) containing 5% IL-7–containing conditioned media from the
J558L–IL-7 cell line (25), 10% FBS (Biologos, Montgomery, IL), 13
penicillin/streptomycin/L-glutamine (Lonza, Shawinigan, Quebec, Canada),
and 5 3 1025 M 2-ME (Sigma-Aldrich, St. Louis, MO). Purified recombinant growth factors were purchased from PeproTech (Embrun, ON,
Canada) and used at the following concentrations: murine stem cell
factor (100 ng/ml), murine M-CSF (10 ng/ml), murine IL-3 (10 ng/ml),
murine IL-6 (10 ng/ml), murine GM-CSF (1 ng/ml), murine Flt-3 ligand
(20 ng/ml), murine IL-7 (100 ng/ml), and murine G-CSF (10 ng/ml).
WEHI-279 B cell lymphoma cells were maintained in complete DMEM
(Lonza) containing 4.5 g/l glucose. ST2 stromal cells were maintained in
complete IMDM. Plat-E retroviral packaging cells and NIH-3T3 cells were
maintained in complete DMEM containing 1.5 g/l glucose. All cell lines
were maintained in 5% CO2 atmosphere and at 37˚C.

BLNK IS REGULATED BY PU.1 AND Spi-B
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bar) was still extensively infiltrated with CD19+ IL-7Ra+ cells.
CD19+ B-ALL cells were negative for c-Kit and expressed low
levels of cell-surface IgM (data not shown). IL-7Ra+ B-ALL cells
expressed the pre-B cell markers BP-1 (33), AA4.1/CD93 (34),
and variable levels of B220 (Fig. 1D). To determine whether there
was functional IL-7R signaling in IL-7Ra+ B-ALL cells, we determined the status of Akt phosphorylation (35). Immunoblotting
of lysates prepared from the tissues of 11- to 18-wk-old DPB mice
showed increased levels of phosphorylated and total Akt protein
compared with DB mice in either spleen (Fig. 1E) or thymus (Fig.
1F), suggesting active IL-7R signaling in these cells. B-ALL cells
from 11- to 18-wk-old DPB mice were B220+ or were a mixture of
B220+ and B2202 cells (Fig. 1D, right panel; Fig. 1G). However,
.40% of B-ALLs from mice between 19 and 23 wk of age were
exclusively B2202 (Fig. 1G). These results suggest that expression of B220 on B-ALL cells was progressively lost as DPB mice
aged. Cd45, encoding B220, has been shown to be a PU.1 target
gene, so it is expected that the loss of B220 is a consequence of
Sfpi1 deletion (36). In summary, the incidence of thymus enlargement in DPB mice increased with age, and the B-ALL cells
that infiltrated the thymus in DPB mice expressed functional IL7R.

(Fig. 2A). Cells from the enlarged thymuses of 19- to 23-wk-old
DPB mice generated colonies in IL-7–containing methylcellulose
at a frequency of ∼50 per 50,000 cells, suggesting that IL-7 was
sufficient to induce proliferation in a manner that did not require
cell–cell contact. After expansion, these cells had the typical small
and highly refractile appearance of pro-B/pre-B cells, and could
be efficiently expanded and propagated as cell lines (Fig. 2B).
DPB B-ALL cells proliferated in response to either IL-7–conditioned media or purified rIL-7 (Fig. 2C). However, established
DPB B-ALL cell lines did not proliferate in response to cell
culture media alone, stem cell factor, Flt3 ligand, IL-3, M-CSF, or
GM-CSF (Fig. 2C). Cultured DPB B-ALL cells lines expressed
CD19, BP-1, and AA4.1/CD93 (data not shown), as well as IL7Ra and surface IgM (Fig. 2D). Cultured cells did not express
detectable c-Kit but did express cell-surface pre-BCR as detected
by Ab SL156 (Fig. 2D). Because c-Kit is considered a marker for
pro-B cells that is lost on differentiation into pre-B cells (37),
these results are most consistent with a description of IL-7–dependent cell lines established from DPB B-ALL as pre-B cells. In
summary, IL-7 is both necessary and sufficient for the ex vivo
growth of pre-B–like cell lines from the thymus of 19- to 23-wkold DPB mice.

IL-7–dependent pre-B cell lines can be established from the
thymus of DPB mice

The Blnk gene is activated by PU.1 and/or Spi-B

Expression of functional IL-7R by B-ALL cells in DPB thymus
suggested that these cells might proliferate in response to IL-7 in
culture. We tested whether B-ALL cells from the enlarged thymus
of 19- to 23-wk-old DPB mice could proliferate in response to
complete media, ST2 stromal cells, IL-7, or ST2 stromal cells and
IL-7. As controls, thymocytes from age-matched littermate DB
mice were cultured under the same conditions. Control DB thymocytes did not grow in culture in any condition. In contrast,
DPB cells proliferated in response to IL-7 alone or ST2 + IL-7

We previously reported that B-ALL cells from DPB mice express
reduced levels of mRNA transcripts encoding BLNK relative to
control B cells (15). Because mutation of Blnk is sufficient to
induce B-ALL in mice (23, 24), we sought to determine whether
Blnk is a target of gene activation by PU.1, and Spi-B. IL-7–dependent DPB B-ALL cell lines expressed reduced levels of BLNK
protein compared with wild type IL-7–dependent pro-B cells (Fig.
3A). DPB B-ALL cell lines expressed 10-fold reduced steady-state
levels of Blnk mRNA transcripts compared with wild-type IL-7–
dependent pro-B cells (Fig. 3B). Phylogenetic comparisons of
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FIGURE 1. Age-dependent appearance of IL-7Ra–
expressing B-ALL cells in the thymus of DPB mice. (A)
Enlarged thymuses in DPB mice at various ages. The yaxis indicates percentage of mice with enlarged thymuses in the age groups indicated on the x-axis. (B)
Increased thymic weight in DPB mice. The total weight
of the thymus in grams was compared in DB (n = 7) and
DPB mice (n = 9) between 19 and 23 wk of age. ***p ,
0.001 by Student t test. (C) Expression of IL-7Ra by
tumor cells in enlarged thymuses. The y-axis indicates
percentage of mice in which the frequency of IL-7Ra–
expressing thymocytes was .60%, in age groups indicated on the x-axis. (D) Coexpression of IL-7Ra with
immature B cell markers in DPB mice. Flow cytometric
analysis was performed to determine expression of the
indicated markers. Increased brightness of IL-7Ra in the
third panel is a consequence of using Cy7 rather than PE
as a fluorophore. (E and F) Increased levels of total and
phosphorylated Akt (pAkt) in DPB B-ALL cells. Immunoblotting for pAkt, total Akt (Akt), or b-actin was
performed on lysates prepared from the spleen or thymus of a 16-wk-old DPB mouse, as well as from a DB
control. Bone marrow cells cultured in IL-7 were used as
a positive control for Akt activation. Result shown is
representative of two experiments performed. (G) Progressive loss of B220 expression on leukemic B cells in
enlarged thymus of DPB mice. The y-axis indicates the
percentage of mice in each age group in which the enlarged thymus contained either B220+ cells (B220pos),
B2202 cells (B220neg), or a mixture of both B220+ and
B2202 cells (mixed).
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DNA sequences in the previously described mouse Blnk promoter
region (38), as well as analysis using a position weight matrix
algorithm (27), were used to identify predicted PU.1/Spi-B binding sites. Three PU.1 and/or Spi-B binding sites were predicted
based on high matrix similarity scores (Fig. 4A). Interestingly, the
site with the highest matrix similarity score was located near the
published transcription start sites of the Blnk gene and near
binding sites for Pax5 (38) (Fig. 4A). A 418-bp segment of the
murine Blnk promoter that displayed high mouse–human similarity was amplified and cloned from C57BL/6 B cell genomic
DNA. The Blnk promoter was tested for activity by transient
transfection in WEHI-279 B lymphoma cells and showed activity
only in the forward orientation (Fig. 4B and data not shown).
Mutation of the highest scoring predicted binding site from
GGAA to GGAC (Fig. 4C) reduced Blnk promoter activity by 3fold (Fig. 4B). Therefore, the Blnk promoter contains a potential
PU.1 and/or Spi-B binding site.
To determine whether PU.1 or Spi-B can directly interact with
the Blnk promoter in B cells, we performed ChIP experiments.

FIGURE 3. DPB B-ALL cells express reduced levels of BLNK. (A)
Reduced levels of BLNK protein in DPB B-ALL cells. Immunoblot was
used to compare relative levels of BLNK protein in two independent DPB
B-ALL cell lines relative to IL-7–dependent wild type pro-B cells. As
a loading control, levels of b-actin protein were determined by immunoblot (lower panel). (B) Reduced levels of Blnk mRNA transcripts in DPB
B-ALL cells. RT-qPCR was used to compare relative levels of Blnk mRNA
transcripts in DPB B-ALL cells compared with IL-7–dependent wild-type
pro-B cells. Transcript levels were normalized to b2-microglobulin mRNA
transcript levels. ***p , 0.001 by Student t test.

Because anti–Spi-B Abs were not available, WEHI-279 B lymphoma clones were generated expressing GFP and 3XFLAGtagged full-length PU.1 or Spi-B protein under the control of a
retroviral long terminal repeat promoter (Fig. 5A, 5B). As a negative control, a WEHI-279 clone expressing only GFP (MIGR1)

FIGURE 4. Blnk is transcriptionally activated by PU.1 and/or Spi-B. (A)
Schematic of the Blnk promoter region. Major transcription start sites are
indicated by arrowheads. Predicted PU.1/Spi-B binding sites are indicated
by boxes. Numbers indicate matrix similarity scores. Underlined sequences
represent previously identified Pax5 binding sites. (B) Reduced Blnk promoter activity after mutagenesis of a predicted PU.1/Spi-B binding site.
The Blnk promoter fragment shown in (A) was tested for activity in a luciferase assay with either an intact PU.1/Spi-B binding site (BLNKp) or
the site mutated as shown in (C) (BLNKp-Mut). **p , 0.01 by Student t
test. (C) Site-directed mutagenesis of a predicted PU.1/Spi-B binding site.
MUT, Mutated DNA sequence.
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FIGURE 2. Establishment of IL-7–dependent
cell lines from thymocytes of DPB mice. (A) IL-7
is sufficient to promote proliferation of DPB BALL cells. B-ALL cells from the enlarged thymus of 17-wk-old DPB or DB mice were placed
in culture with IL-7 or IL-7 and ST2 stromal
cells, and counted after 7 d. One representative
experiment of five performed is shown. (B) Appearance of cultured DPB cells. Cells were photographed at 340 original magnification using a
Zeiss AxioVert inverted microscope under phasecontrast illumination. (C) IL-7 is both necessary
and sufficient for proliferation of DPB B-ALL
cells. Cells that had been grown for several passages in IL-7 were washed and cultured at 106
cells/flask in media containing cytokines indicated on the x-axis and counted after 4 d. (D)
Cell-surface phenotype of IL-7–dependent DPB
B-ALL cells. Flow cytometry was used to determine expression of the markers indicated on the
x-axis. The open histogram indicates staining
with isotype control Ab, whereas the filled histogram indicates staining with the indicated Ab.
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was also generated (Fig. 5B). WEHI-279 cells infected with MIG3XFLAG-PU.1 retrovirus expressed 2- to 3-fold higher PU.1
protein levels and 1.3-fold higher Sfpi1 mRNA transcript levels
than controls (Fig. 5C, 5D). A WEHI-279 clone infected with
MIG–3XFLAG–Spi-B was selected for expression of FLAGtagged Spi-B at levels comparable with FLAG-tagged PU.1, and
was found to express Spib mRNA transcripts at 3.6-fold higher
levels than endogenous Spib transcript levels in control cells
(Fig. 5C, 5D). ChIP was performed on fixed WEHI-279 clonal
cell lines using anti-FLAG mAb. qPCR was performed on
immunoprecipitated DNA to determine association of regulatory
regions with 3XFLAG-tagged PU.1 or Spi-B. Enrichment was
compared with DNA immunoprecipitated from MIGR1 cells using
anti-FLAG Ab. The promoter of the Hprt gene, which was not
expected to be associated with PU.1 or Spi-B, was not significantly enriched by immunoprecipitation with anti-FLAG Ab (Fig.
5D, 5E). In contrast, intronic enhancers of the Mef2c and Igh loci,
which are highly expressed in the B cell lineage under control of
PU.1 (39, 40), were enriched in cells expressing FLAG-tagged

PU.1 and Spi-B (Fig. 5D, 5E). PU.1 and Spi-B were associated
with the Blnk promoter, showing enrichment by 10- and 13-fold
compared with the negative control, respectively (Fig. 5D, 5E).
Reanalysis of published ChIP-sequencing data using anti-PU.1 in
murine B cells (41) confirmed that endogenous PU.1 interacts
with the site we identified in the Blnk promoter (data not shown).
Taken together, these results suggest that PU.1 and Spi-B activate
Blnk transcription by direct interaction with the Blnk promoter.
Forced expression of BLNK opposes the growth of cultured
DPB B-ALL cells
If transformation of DPB cells is, in part, a consequence of reduced BLNK expression, then restoration of BLNK expression
might be expected to oppose growth of these cells in vitro. To test
this idea, we used RT-PCR to amplify the full Blnk coding sequence from C57BL/6 splenic B cell RNA. Blnk cDNA was
cloned and ligated into the retroviral vector MIGR1 to promote
expression of BLNK protein, as well as enhanced GFP under
control of the retroviral long terminal repeat promoter (Fig. 6A).
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FIGURE 5. Interaction of PU.1 and Spi-B with the Blnk promoter. (A) Schematic of retroviral vectors. (B) Flow cytometric analysis of WEHI-279 clones
expressing GFP only (MIGR1), FLAG-tagged PU.1 and GFP, or Spi-B and GFP. (C) Expression of FLAG-tagged proteins by WEHI-279 clones. Immunoblot was performed on lysates from the clones described in (A) using anti-FLAG Ab (upper panel), anti-PU.1 Ab (center panel), or anti–b-actin Ab
(lower panel). (D) Increase in steady-state levels of transcripts encoding PU.1 and Spi-B in infected WEHI-279 cells. RT-qPCR was performed to determine
relative levels of the indicated transcripts in WEHI-279 cells infected with control retrovirus (MIGR1) or retrovirus encoding PU.1 (3XFLAG-PU.1) or SpiB (3XFLAG–Spi-B). (E and F) ChIP analysis. Chromatin prepared from the clones described in (A)–(D) was immunoprecipitated with anti-FLAG Ab.
Immunoprecipitated DNA was quantified by relative qPCR using primers recognizing the hypoxanthine-guanine phosphoribosyltransferase promoter
(Hprt), Mef2c enhancer (Mef2c), IgH intronic enhancer (Em), or Blnk promoter (Blnk). Amounts of immunoprecipitated DNA are expressed as percentage
of input. Enrichment was calculated as the fold change in percentage of input. Results shown are representative of three independent experiments.
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BLNK protein was expressed in NIH-3T3 cells infected with the
MIG-BLNK retrovirus (Fig. 6B). To determine whether forced
BLNK expression opposes proliferation of cultured DPB B-ALL
cells, we infected cultured DPB cells with MIG-BLNK retrovirus
or with MIGR1 retrovirus as a control. Infected cells were cultured 48 h to promote retroviral integration, and the frequency of
cells expressing GFP was determined by flow cytometry on passage every 72–96 h. The relative frequency of MIGR1-infected
cells changed no more than 1.2-fold for the duration of the experiment. In contrast, the relative frequency of MIG-BLNK–
infected cells was reduced with each passage until termination of
the experiment (Fig. 6C). This result suggested that BLNKinfected DPB cells proliferated poorly compared with MIGR1infected cells. To confirm this finding, we placed MIGR1- or
MIG-BLNK–infected DPB cells in methylcellulose colonyforming assays with IL-7. After 7 d, GFP2 and GFP+ colonies were counted using an inverted fluorescence microscope. The
frequency of GFP+ colonies generated by MIGR1-infected cells
was similar to the frequency of GFP+ cells placed in the assay as
determined by flow cytometry. In contrast, no GFP+ colonies were
generated from MIG-BLNK–infected DPB cells. To determine
why BLNK-infected DPB cells failed to proliferate, we measured
early apoptosis using Annexin V staining 48 h after retroviral
infection. A high frequency of MIG-BLNK–infected cells stained
positively with Annexin V compared with MIGR1-infected cells
(Fig. 6D). We conclude that restoration of BLNK expression using
a retroviral vector opposes IL-7–dependent proliferation of DPB
B-ALL cell lines, at least, in part, by inducing early apoptosis.

Discussion
This study explored the mechanism by which deletion of genes
encoding PU.1 and Spi-B induces B-ALL in mice. We showed that
B-ALL cells from the enlarged thymus of DPB mice express IL-7R
on their surface and can be grown ex vivo in response to IL-7.
Second, we showed that the gene encoding BLNK is a direct target

of activation by PU.1 and/or Spi-B. These results suggest that
PU.1 and Spi-B are complementary activators of Blnk transcription, and that B-ALL is induced in DPB mice, at least in part, as
a consequence of reduced BLNK levels.
PU.1 and Spi-B have both been implicated as oncogenes or
tumor suppressors, depending on the circumstance. PU.1 was
discovered as a gene upregulated in murine erythroleukemia as
a consequence of proviral insertion by the murine SFFV retrovirus
(42). Overexpression of PU.1 has also been implicated as a cause
of T cell leukemia in genetically modified mice (43). In contrast,
reduced levels of PU.1 caused by mutation or repression of the
Sfpi1 gene are sufficient to induce acute myeloid leukemia (8, 44).
Spi-B is frequently overexpressed in diffuse large B cell lymphoma (45). Therefore, PU.1 and Spi-B have known functions as
either oncogenes or tumor suppressors, but little is known about
the mechanism of these functions. We expect that PU.1 and Spi-B
transcriptionally activate downstream target genes with tumorsuppressor function.
BLNK is considered a tumor suppressor because: 1) point
mutations or reduced levels of BLNK are associated with human
B-ALL (21–23), and 2) mutation of Blnk is sufficient to induce
B-ALL in mice (24, 46). However, BLNK is required for B cell
development in mice and humans, causing primary human
B cell deficiency when mutated (16, 20). BLNK is required for
B cell development because it links signals from the pre-BCR or
BCR with B cell differentiation by functioning as an adaptor or
scaffold to promote interaction of key signaling proteins (20).
Several recent studies suggest that BLNK has a dual function of
enforcing BCR signaling whereas blocking IL-7 signaling (35, 46,
47). BLNK interacts directly with JAK3, promoting the uncoupling of JAK3 from IL-7 signaling (46). BLNK also inhibits activation of the PI3K-Akt pathway downstream of IL-7R signaling
(35, 47). Therefore, reduced BLNK levels, as might be induced by
mutation, repression, or reduced transcriptional activation, would
be expected to result in increased IL-7R signaling, as well as reduced BCR signaling, promoting proliferation and impairing differentiation (35, 46).
Addiction to IL-7 signaling may be a common feature of pediatric leukemia. Human B-ALL tumor cells frequently express
functional IL-7R on their surface and can respond to IL-7 in culture
(48). Gain-of-function mutations in the IL7R gene (encoding IL7Ra) are associated with pediatric ALL (49). In mice, overexpression of IL-7 is sufficient to induce lymphoproliferation
leading to leukemia (50). As described in Results, B-ALL cells in
DPB mice express high levels of IL-7R on their surface and grow
readily in response to IL-7 ex vivo. These results suggest that IL7R expression and IL-7 signaling plays a role in development of
leukemia in DPB mice. Developing B cells express high levels of
IL-7Ra, but this receptor is not expressed by mature B cells (51).
Little is known about what factors control transcriptional downregulation of IL7R in developing B cells; however, we speculate
that BLNK might be involved in regulation of IL-7Ra expression,
as well as downstream signaling. B-ALL cells from Blnk2/2 mice
express IL-7R on their surface and can be efficiently propagated in
culture in response to IL-7 (23, 24). In addition, Blnk2/2 B-ALL
cells grow in autocrine fashion, both producing and proliferating
in response to IL-7 (46). Therefore, in the absence of BLNK, preB cells might have sustained IL-7R signaling as a consequence of
a failure to inhibit IL-7R signaling, as well as a failure to appropriately downregulate IL-7Ra expression.
Our findings suggest that activation of BLNK expression is an
important pathway by which PU.1 and/or Spi-B regulate B cell
differentiation. B cells deficient in PU.1 and/or Spi-B have severely impaired BCR signaling (52) and, as a consequence, cannot
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FIGURE 6. Forced expression of BLNK opposes IL-7–dependent proliferation of DPB B-ALL cells. (A) Schematic of the MIG-BLNK retroviral
vector. (B) Expression of BLNK protein in NIH-3T3 cells infected with
retroviral vectors. Immunoblot was used to determine BLNK expression in
NIH-3T3 cells infected with either MIGR1 or MIG-BLNK. (C) Reduced
frequency of MIG-BLNK–infected DPB B-ALL cells upon serial passage.
Flow cytometry was used to determine the percentage of cells infected
with MIGR1 (triangles) or MIG-BLNK (squares) at the time points shown
on the x-axis. The y-axis shows relative infection frequencies normalized
to the frequency of infected cells at 48 h. (D) Increased apoptosis of MIGBLNK–infected DPB B-ALL cells 48 h postinfection. Cells were stained
with Annexin V and analyzed using flow cytometry. Results are shown
gated on GFP+ cells.
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mice (55). These results suggest that PU.1 and Spi-B increase
BLNK and Btk levels to enforce B cell differentiation and oppose
oncogenic transformation.
B-ALL is frequently associated with chromosomal translocations that result in generation of abnormal transcription factors.
Twenty-five percent of cases of pre-B ALL involve the t(12;21)
chromosomal translocation that results in an ETV6-RUNX1 (also
known as TEL-AML1) fusion gene (1). The significance of this
observation to this study is that RUNX1 is an important upstream
activator of the SPI1 gene in humans and the Sfpi1 gene in mice
(56). PU.1 levels are reduced upon expression of RUNX1 fusion
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